Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Therapeutic effects of miR-937-3p by targeting NTN1 expression and regulating apoptosis in an Aβ-induced neuronal cell death

Choi J., Jeong H., Ramalingam M., Hwang J., Kim SJ., Kim BC.

Animal Study on Neuroinflammation, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40604203
PMCID
PMC12223061
DOI
10.1038/s41598-025-08015-0

Abstract (original English)

MicroRNAs (miRNAs) have multiple functions that regulate gene expression in various species. Few studies have explored the effects of miRNAs on the pathogenesis of Alzheimer's disease (AD); however, the potential neuroprotective effects of miRNAs on AD, particularly by targeting neuronal markers, remain unclear. In this study, we suggested potential neuroprotective roles for miR-937-3p in an in vitro AD model, which has not been extensively studied. Our biological analysis confirmed that miR-937-3p participated in neuronal protection and differentiation. We selected miR-937-3p as a novel candidate and identified Netrin1 (NTN1), an axon guidance regulator, as its target gene via qPCR analysis and luciferase assay. Additionally, FACS analysis revealed a reduction in apoptosis levels in Aβ-treated cells following treatment with the miR-937-3p-I. Western blot analysis showed that the expression of Mcl-1, an anti-apoptotic marker, increased with miR-937-3p-I treatment in an in vitro AD model. Interestingly, the levels of pro-caspase 7, pro-caspase 3, and pro-PARP, which are usually downregulated when their cleaved forms are upregulated, were found to increase with miR-937-3p-I treatment. The expression levels of neuronal markers such as NeuN, NFH, Tuj1, SYP, and MAP2 were enhanced by miR-937-3p-I treatment in the in vitro AD model. Therefore, miR-937-3p inhibition might play a thera

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
NeuronsAnimalsHumansAlzheimer DiseaseMicroRNAsApoptosisGene Expression RegulationAmyloid beta-PeptidesMyeloid Cell Leukemia Sequence 1 ProteinNetrin-1

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research